ClinicalTrials.gg
RecruitingNCT06559150Updated Oct 27, 2026

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

A Phase 2 interventional study of Nebulized Ensifentrine Suspension; 3 mg and Nebulized Placebo Solution in Non-cystic Fibrosis Bronchiectasis, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Recruiting at 51 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 27, 202611 sites added11 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Planned enrollment
14th of 52
284 · median 78
Started
2024
with 7 others
Phase 2
15 of 65
4 open now
Primary completion
2027-09
later than 13 of 21 live
Registered
53rd of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 14th largest by planned enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2024, is one of 15 in phase 2, reaches primary completion later than 13 of the 21 other live ones, and was the 53rd registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).

Read the detailed description

The primary objective of this study is to assess the effect of ensifentrine vs placebo in addition to standard of care on pulmonary exacerbations, symptoms and quality of life in participants with NCFBE.

Participants will be treated for up to 52 weeks (some subjects may end earlier as the sponsor may end the study after the last subject in the study completes the Week 24 visit).

Participants will be randomized to receive either ensifentrine suspension or placebo via standard jet nebulizer during the treatment period and neither participants nor study staff will know which a participant is receiving.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males are eligible to participate if they agree to use as described in the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication
  • Females are eligible to participate if they are not pregnant, not breastfeeding, and 1 of the following conditions apply:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance from Screening throughout the study and for at least 30 days after the last dose of blinded study medication
  • Clinical history consistent with bronchiectasis (cough, chronic sputum production, and/or recurrent respiratory infections) confirmed by chest CT demonstrating bronchiectasis affecting 1 or more lobes. Confirmation may be based on prior chest CT within the prior 5 years; subjects whose past CT image records are not available will require chest CT scan during screening Notes: If a subject has no clinical history consistent with bronchiectasis, they may not be re-screened
  • Current sputum producer with a history of chronic expectoration and able to provide sputum sample spontaneously at the clinic during screening
  • ≥ 1 documented pulmonary exacerbation defined by an antimicrobial prescription (i.e., antibiotic or antiviral) by a physician for the signs and symptoms of respiratory infections in the past 12 months before screening
  • Capable of using the study nebulizer correctly
  • Ability to perform acceptable spirometry in accordance with American Thoracic Society and European Respiratory Society guidelines as assessed by the Investigator

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of or a primary diagnosis of asthma, as judged by the investigator
  • Bronchiectasis due to cystic fibrosis, primary hypogammaglobulinemia common variable immunodeficiency, severe immunodeficiency, or requirement for treatment with intravenous immunoglobulin
  • Current smoker defined as by the Centers for Disease Control and Prevention (CDC)
  • Meets both of the following

    1. Former cigarette smokers with a history of cigarette smoking ≥ 10 pack years at Screening [number of pack years = (number of cigarettes per day / 20) × number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Screening AND
    2. Evidence within 1 year prior to randomization of obstructed lung function as shown by (FEV1)/forced vital capacity (FVC) ratio of \< 0.70
  • A diagnosis of primary ciliary dyskinesia (PCD) is not exclusionary. Subjects with a diagnosis of PCD are permitted to be enrolled, but the proportion of subjects with PCD enrolled in the study may be limited
  • Current treatment for nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis
  • Presence of acute exacerbation or acute infection that required acute treatment within 28 days of randomization
  • Use of the following prohibited medications within the designated time periods:

    1. Chronic, systemic immunomodulatory agents for any chronic indication (including but not limited to the following: methotrexate, systemic , see adalimumab, azathioprine, dupilumab, cyclosporine, hydroxychloroquine, etc.) within 90 days prior to signing the ICF
    2. CFTR modulators (e.g., ivacaftor, lumacaftor, tezacaftor) within 1 week prior to signing the ICF
    3. Theophylline and oral PDE4 inhibitors (e.g., roflumilast, apremilast, crisaborole) within 48 hours prior to signing the ICF
    4. Ohtuvayre at any time prior to signing the ICF
  • Initiated or altered therapy within 90 days prior to randomization with:

    1. oral or inhaled antibiotics as chronic treatment (including macrolides)
    2. Cyclic antibiotics: defined as prescribed regular cycles of on antibiotic treatment and off antibiotic treatment (for example, but not limited to, 28 days on an antibiotic and 28 days off an antibiotic). Note: Subjects on cyclic antibiotics must be actively taking antibiotics for at least 7 days prior to randomization through the day of randomization
    3. Dipeptidyl peptidase 1 (DPP1) or cathepsin C (CatC) inhibitor (e.g., brensocatib)
  • Initiated or altered therapy with ICS within 4 weeks prior to randomization
  • Unable to withhold short-acting beta-agonists or short-acting muscarinic antagonists for ≥ 4 hours prior to spirometry
  • Significant hemoptysis (≥ 300 mL or requiring blood transfusion) within 6 weeks prior to randomization
  • Currently participating in or scheduled to participate in an intensive pulmonary rehabilitation program (a maintenance rehabilitation program is allowed if their schedule and procedure will be consistent for the duration of the study)
  • Current or chronic history of unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, or known hepatic or biliary abnormalities except for Gilbert syndrome or asymptomatic gallstones Note: Chronic stable and C is not exclusionary if the subject otherwise meets study entry criteria
  • History of or current of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin
  • Estimated (eGFR) \< 30 mL/min
  • (ALT) ≥ 2 × (ULN), aspartate aminotransferase (AST) ≥ 2 × ULN, alkaline phosphatase and/or > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable only in subjects with a diagnosis of Gilbert's syndrome)
  • Participation in any other interventional, clinical studies (drugs or devices) within 30 days, or 5 half-lives, whichever is longer, prior to signing the ICF
  • Intolerance of or to ensifentrine or any of its /components
  • Current or history of drug or alcohol abuse within the past 5 years
  • Significantly abnormal finding
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
284 participants (estimated)

Study arms

  • Experimental
    Treatment Arm 1: Ensifentrine

    Drug: Nebulized Ensifentrine Suspension; 3 mg

  • Placebo comparator
    Treatment Arm 2: Placebo

    Drug: Nebulized Placebo Solution

Interventions

  • DrugNebulized Ensifentrine Suspension; 3 mg

    Administered by a standard jet nebulizer, twice daily up to a maximum of 52 weeks

  • DrugNebulized Placebo Solution

    Administered by a standard jet nebulizer, twice daily up to a maximum of 52 weeks

06

What researchers measure

Primary outcomes

  1. Rate of protocol-defined pulmonary exacerbations (number of events per subject-year)

    Time frame: Through study completion (up to 52 weeks)

Secondary outcomes

  1. Time to the onset of the first protocol-defined pulmonary exacerbation

    Time frame: Through study completion (up to 52 weeks)

  2. Change from Baseline in Evaluating Respiratory Symptoms (E-RS) Cough and Sputum Domain score

    The E-RS is a patient reported outcome that is derived from the EXAcerbation of Chronic Pulmonary Disease Tool (EXACT)-PRO in the participants e-diary, to quantify the severity of symptoms. The score ranges from 0 to 40 with a higher score representing more severe symptoms.

    Time frame: Baseline, Week 6, Week 12, and Week 24

  3. Change from Baseline in Saint George's Respiratory Questionnaire (SGRQ) total score

    SGRQ scores range from 0 to 100, with a higher score representing worse health.

    Time frame: Baseline, Week 6, Week 12, and Week 24

  4. Change from Baseline in quality of life - bronchiectasis questionnaire (QOL-B) Respiratory Symptoms Domain score

    The QOL-B Respiratory Symptoms Domain score ranges from 0 to 100, with higher scores representing better functioning.

    Time frame: Baseline, Week 6, Week 12, and Week 24

  5. Change from Baseline in Chronic Airways Assessment Test (CAAT) total score

    CAAT scores range from 0-40 with a higher score representing worse health.

    Time frame: Baseline, Week 6, Week 12, and Week 24

  6. Change from Baseline in Percent of the predicted forced expiratory volume over 1 second (FEV1)

    Time frame: Baseline, Week 12, and Week 24

  7. Change from Baseline of forced vital capacity (FVC)

    Time frame: Baseline, Week 12, and Week 24

  8. Incidence of Adverse Events

    Time frame: Through study completion (approximately 52 weeks)

  9. PK Sub-study only: Ensifentrine area under the curve from time 0 to 12 hours (AUC 0 -12)

    Time frame: Week 12, Week 18, and Week 24

  10. PK Sub-study only: Ensifentrine maximum plasma drug concentration (Cmax)

    Time frame: Week 12, Week 18, and Week 24

  11. Pharmacokinetic (PK) Sub-study only: Ensifentrine time to Cmax (tmax) post morning dose

    Time frame: Week 12, Week 18, and Week 24

07

Study locations

50 of 51 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 19, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Sep 24, 2027
CompletionEst.
Sep 24, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 11 sites removed
Show 11 added (7 Spain, 2 Italy, 2 United Kingdom)
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Hospital Universitario A Coruña · A Coruña, Spain
  • Hospital del Mar · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Universitario Vall d'Hebron - PPDS · Barcelona, Spain
  • Hospital Universitario de Bellvitge · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario La Paz - PPDS · Madrid, Spain
  • Ninewells Hospital - PPDS · Dundee, United Kingdom
  • Queen Elizabeth University Hospital - PPDS · Glasgow, United Kingdom
Show 11 removed
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Hospital Universitario A Coruña · A Coruña, Spain
  • Hospital del Mar · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Universitario Vall d'Hebron - PPDS · Barcelona, Spain
  • Hospital Universitario de Bellvitge · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario La Paz - PPDS · Madrid, Spain
  • Ninewells Hospital - PPDS · Dundee, United Kingdom
  • Queen Elizabeth University Hospital - PPDS · Glasgow, United Kingdom
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    11 sites added, 11 sites removed
    Show 11 added (7 Spain, 2 Italy, 2 United Kingdom)
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Hospital Universitario A Coruña · A Coruña, Spain
    • Hospital del Mar · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Universitario Vall d'Hebron - PPDS · Barcelona, Spain
    • Hospital Universitario de Bellvitge · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario La Paz - PPDS · Madrid, Spain
    • Ninewells Hospital - PPDS · Dundee, United Kingdom
    • Queen Elizabeth University Hospital - PPDS · Glasgow, United Kingdom
    Show 11 removed
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Hospital Universitario A Coruña · A Coruña, Spain
    • Hospital del Mar · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Universitario Vall d'Hebron - PPDS · Barcelona, Spain
    • Hospital Universitario de Bellvitge · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario La Paz - PPDS · Madrid, Spain
    • Ninewells Hospital - PPDS · Dundee, United Kingdom
    • Queen Elizabeth University Hospital - PPDS · Glasgow, United Kingdom
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06559150
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Sep 11, 2024
Primary completion
Sep 24, 2027 (estimated)
Completion
Sep 24, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway Toll Free Number
Contact
Trialsites@msd.com
Reach out by phone or email ext. 1-888-577-8839

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion